December 26, 2002
Gilead Sciences And Triangle Pharmaceuticals Announce Expiration Of Hart-Scott-Rodino Waiting Period

December 17, 2002
Gilead Sciences to Provide Access to Anti-HIV Therapy Viread^® in 68 Developing World Countries at No Profit

December 13, 2002
Gilead to Receive $300 Million from Offering of Convertible Notes

December 12, 2002
Gilead to Raise $300 Million from Offering of Convertible Notes

December 4, 2002
Gilead Sciences to Acquire Triangle Pharmaceuticals for $464 Million

November 21, 2002
European CPMP Gives Positive Opinion on Hepsera, Gilead's Treatment for Chronic Hepatitis B

November 4, 2002
New Data Demonstrate Antiviral Activity of Gilead's Hepsera in Patients with Lamivudine-Resistant Chronic Hepatitis B

October 31, 2002
Gilead Sciences Announces Third Quarter 2002 Financial Results

October 28, 2002
Gilead Sciences to Release Third Quarter 2002 Financial Results on Thursday, October 31, 2002

October 28, 2002
Bill & Melinda Gates Foundation Grant to Evaluate Once-Daily Antiretroviral as a Potential Method of HIV Prevention

September 27, 2002
Phase III Study of Viread^® Shows Favorable Lipid and Mitochondrial DNA Profile in Treatment-Naïve HIV Patients

September 20, 2002
FDA Approves Gilead’s Hepsera^™ for the Treatment of Chronic Hepatitis B

September 9, 2002
Cubist and Gilead End European Commercialization Agreement for Investigational Antibiotic Cidecin®

August 28, 2002
Hepsera^™ Selected as U.S. Trade Name for Adefovir Dipivoxil

August 6, 2002
FDA Advisory Committee Unanimously Supports Approval of Gilead’s Adefovir Dipivoxil to Treat Chronic Hepatitis B

August 5, 2002
Gilead Announces Posting of FDA Briefing Documents for August 6 Advisory Committee Review of Adefovir Dipivoxil for Chronic Hepatitis B

July 24, 2002
Gilead Sciences Announces Second Quarter 2002 Financial Results

July 19, 2002
Gilead Sciences to Release Second Quarter 2002 Financial Results on Wednesday, July 24, 2002

July 11, 2002
48-Week Data Demonstrate Ability of Viread to Suppress Viral Load in Patients with Multiple Treatment-Resistant HIV Mutations

July 8, 2002
48-Week Data Compare Viread to Stavudine When Used as Part of Patients’ First Anti-HIV Regimen

June 26, 2002
Roche Receives Approval In Europe For Tamiflu^®

June 18, 2002
Gilead Sciences Announces Acceptance of Viread Late Breaker Abstracts at Upcoming 14th International AIDS Conference

June 10, 2002
Anadys Forms Collaboration With Gilead To Discover Novel Antiviral Compounds

May 21, 2002
Gilead Announces Initiation of NIH-sponsored Phase I Trial to Evaluate Tenofovir Topical Gel as Preventive for Vaginal Transmission of HIV

May 21, 2002
Gilead Announces Initiation of NIH-Sponsored Phase I Trial to Evaluate Tenofovir Topical Gel as Preventive for Vaginal Transmission of HIV

May 7, 2002
Gilead Announces Preliminary 48-Week Study Results Showing Viread Comparable to Stavudine in Treatment-Naïve HIV Patients

April 30, 2002
Gilead Sciences Announces First Quarter 2002 Financial Results

April 29, 2002
Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil

April 19, 2002
Data from Study of Gilead’s Adefovir Dipivoxil in Hepatitis B Patients with Lamivudine-Resistant Virus Presented at International Medical Meeting

April 18, 2002
92-Week Data from Clinical Study of Gilead’s Adefovir Dipivoxil in Patients Co-Infected with HIV and Lamivudine-Resistant HBV Presented at International Medical Meeting

April 18, 2002
Gilead Announces Presentation of Data from Phase III Study of Adefovir Dipivoxil in Patients with Precore Mutant Chronic Hepatitis B

April 15, 2002
Gilead Sciences to Release First Quarter 2002 Financial Results on Tuesday, April 30, 2002

March 29, 2002
Gilead Announces Changes to Senior Management Team

March 26, 2002
Gilead Submits Marketing Authorisation Application for Adefovir Dipivoxil 10 mg for Treatment of Chronic Hepatitis B

March 21, 2002
Gilead Submits New Drug Application to U.S. FDA for Adefovir Dipivoxil 10 mg for the Treatment of Chronic Hepatitis B

March 21, 2002
Roche Receives Positive Recommendation in Europe for Tamiflu^®

March 12, 2002
Gilead Initiates Early Access Program for Adefovir Dipivoxil, Investigational Treatment for Chronic Hepatitis B Infection

February 27, 2002
Gilead Announces Data from Study of Viread^™ in Patients Co-Infected with HIV and HBV

February 25, 2002
Gilead Sciences' Viread^™ Suppresses HIV Viral Load Through 48 Weeks in Phase III Clinical Trial

February 25, 2002
Gilead Launches Web Site for New Anti-HIV Drug Viread^™

February 7, 2002
Gilead Sciences' New HIV Drug Viread^® Approved for Marketing in European Union

January 31, 2002
Gilead Sciences Announces Fourth Quarter and Year End 2001 Financial Results; Product Revenues Increased 57 Percent Over Fourth Quarter 2000

January 31, 2002
Gilead Sciences Announces Fourth Quarter and Year End 2001 Financial Results

January 30, 2002
Gilead Board of Directors Approves Two-For-One Stock Split

January 29, 2002
Gilead Sciences to Release Fourth Quarter and Year-End 2001 Financial Results on Thursday, January 31, 2002